MX2018014920A - Anticuerpos antagonistas antimolécula de orientación repulsiva a (rgma) para el tratamiento de lesion y dolor de la medula espinal. - Google Patents

Anticuerpos antagonistas antimolécula de orientación repulsiva a (rgma) para el tratamiento de lesion y dolor de la medula espinal.

Info

Publication number
MX2018014920A
MX2018014920A MX2018014920A MX2018014920A MX2018014920A MX 2018014920 A MX2018014920 A MX 2018014920A MX 2018014920 A MX2018014920 A MX 2018014920A MX 2018014920 A MX2018014920 A MX 2018014920A MX 2018014920 A MX2018014920 A MX 2018014920A
Authority
MX
Mexico
Prior art keywords
spinal cord
cord injury
pain
rgma
antagonistic antibodies
Prior art date
Application number
MX2018014920A
Other languages
English (en)
Inventor
Klaus Mueller Bernhard
B Jacobson Peer
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018014920A publication Critical patent/MX2018014920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

En este documento se divulgan anticuerpos anti-RGMa y métodos de uso de estos anticuerpos para tratar lesiones de la medula espinal, incluyendo promover la r3egeración axonal, recuperación funcional o ambas o para tratar el dolor, incluyendo dolor neuropatico que surge de lesión de la médula espinal.
MX2018014920A 2016-06-01 2017-05-31 Anticuerpos antagonistas antimolécula de orientación repulsiva a (rgma) para el tratamiento de lesion y dolor de la medula espinal. MX2018014920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344233P 2016-06-01 2016-06-01
PCT/US2017/035183 WO2017210278A1 (en) 2016-06-01 2017-05-31 Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain

Publications (1)

Publication Number Publication Date
MX2018014920A true MX2018014920A (es) 2019-08-26

Family

ID=59078172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014920A MX2018014920A (es) 2016-06-01 2017-05-31 Anticuerpos antagonistas antimolécula de orientación repulsiva a (rgma) para el tratamiento de lesion y dolor de la medula espinal.

Country Status (10)

Country Link
US (3) US20170349653A1 (es)
EP (1) EP3464372A1 (es)
JP (2) JP2019517480A (es)
CN (1) CN109496218A (es)
AU (1) AU2017273522A1 (es)
BR (1) BR112018074966A2 (es)
CA (1) CA3025329A1 (es)
MX (1) MX2018014920A (es)
TW (1) TW201803900A (es)
WO (1) WO2017210278A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821908A4 (en) * 2018-07-10 2022-03-30 Mitsubishi Tanabe Pharma Corporation METHOD OF PREVENTING OR TREATING PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING A DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTIC DISORDER IS RECOGNIZED
CA3112511A1 (en) * 2018-07-19 2020-01-23 The University Of Tokyo Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
DE60137421D1 (de) 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1691835A1 (en) * 2003-11-06 2006-08-23 Icos Corporation Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2331448B1 (es) * 2008-06-25 2010-10-18 Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Complejos de albumina con acidos grasos monoinsaturados omega-9 para el tratamiento de lesiones medulares.
MY176695A (en) * 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
JP2016501881A (ja) * 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質

Also Published As

Publication number Publication date
US20200347123A1 (en) 2020-11-05
CN109496218A (zh) 2019-03-19
JP2019517480A (ja) 2019-06-24
BR112018074966A2 (pt) 2019-03-12
US20220025031A1 (en) 2022-01-27
TW201803900A (zh) 2018-02-01
CA3025329A1 (en) 2017-12-07
JP2022091967A (ja) 2022-06-21
US20170349653A1 (en) 2017-12-07
WO2017210278A1 (en) 2017-12-07
AU2017273522A1 (en) 2018-12-06
EP3464372A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
PH12019500095A1 (en) Compounds, compositions, and methods for the treatment of disease
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
EA201791171A1 (ru) Антитела к tigit
MX2017016253A (es) Anticuerpos para cd40.
MD4716C1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
DE112017000012A5 (de) Finger-bewegungsschiene, halterung hierfür sowie dieses umfassendes therapiegerät und betriebsverfahren
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2020002762A (es) Composiciones y métodos para tratar una lesión cerebral.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EP3801482A4 (en) Methods for treating spinal cord injury
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MX2017000306A (es) Metodos para tratar hipotension.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
HK1244211A1 (zh) 治療、預防或降低皮膚感染風險的方法
MX365899B (es) Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
EA201990988A1 (ru) Антитела против chikv и пути их применения
WO2013150126A3 (de) Verfahren zur behandlung von blut, blutprodukten und organen
EP3423095A4 (en) METHODS FOR TREATING BONE DISEASES AND / OR INJURIES AND REAGENTS THEREFOR
MX2018014920A (es) Anticuerpos antagonistas antimolécula de orientación repulsiva a (rgma) para el tratamiento de lesion y dolor de la medula espinal.
ZA201903747B (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder